Arq. Bras. Cardiol. 2018; 110(4): 399
Incidence of Atrial High-Rate Episodes in Chagas Disease Patients
DOI: 10.5935/abc.20180060
A
t
[…]
Incidence of Atrial High-Rate Episodes in Chagas Disease
Patients
321
How to cite this article
Freitas EL, Sampaio ES, Aras R. Incidence of Atrial High-Rate Episodes in Chagas Disease Patients. Arq. Bras. Cardiol. 2018;110(4):399.
Freitas, Emanoela Lima; Sampaio, Elieusa e Silva; Aras, Roque. Incidence of Atrial High-Rate Episodes in Chagas Disease Patients. Arq. Bras. Cardiol., v. 110, n. 4, p. 399-399, Apr. 2018.
Freitas, E. L., Sampaio, E. S., & Aras, R. (2018). Incidence of Atrial High-Rate Episodes in Chagas Disease Patients. Arq. Bras. Cardiol., 110(4), 399-399.
Freitas, Emanoela Lima and Sampaio, Elieusa e Silva and Aras, Roque. Incidence of Atrial High-Rate Episodes in Chagas Disease Patients. Arq. Bras. Cardiol. [online]. 2018, vol. 110, n. 4, [cited 2025-09-06], pp.399-399. Available from: <https://abccardiol.org/en/article/incidence-of-atrial-high-rate-episodes-in-chagas-diseasepatients/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.